ALNOX.PA
Price:
$0.041
Market Cap:
$0
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combine...[Read more]
Industry
Biotechnology
IPO Date
2018-09-10
Stock Exchange
EURONEXT
Ticker
ALNOX.PA
According to NOXXON Pharma N.V.’s latest financial reports and current stock price. The company's current ROE is -236.45%. This represents a change of -Infinity% compared to the average of 0% of the last 4 quarters.
The mean historical ROE of NOXXON Pharma N.V. over the last ten years is 120.13%. The current -236.45% ROE has changed -296.83% with respect to the historical average. Over the past ten years (40 quarters), ALNOX.PA's ROE was at its highest in in the December 2017 quarter at 68.62%. The ROE was at its lowest in in the January 2014 quarter at 0%.
Average
120.13%
Median
179.40%
Minimum
-320.11%
Maximum
433.55%
Discovering the peaks and valleys of NOXXON Pharma N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 200.21%
Maximum Annual ROE = 433.55%
Minimum Annual Increase = -529.25%
Minimum Annual ROE = -320.11%
Year | ROE | Change |
---|---|---|
2021 | -320.11% | 59.63% |
2020 | -200.53% | -529.25% |
2019 | 46.72% | -88.71% |
2018 | 413.64% | 200.21% |
2017 | 137.78% | -68.22% |
2016 | 433.55% | 89.34% |
2015 | 228.98% | 3.60% |
The current ROE of NOXXON Pharma N.V. (ALNOX.PA) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-157.98%
5-year avg
15.50%
10-year avg
120.13%
NOXXON Pharma N.V.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NOXXON Pharma N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NOXXON Pharma N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is NOXXON Pharma N.V.'s ROE?
How is the ROE calculated for NOXXON Pharma N.V. (ALNOX.PA)?
What is the highest ROE for NOXXON Pharma N.V. (ALNOX.PA)?
What is the 3-year average ROE for NOXXON Pharma N.V. (ALNOX.PA)?
What is the 5-year average ROE for NOXXON Pharma N.V. (ALNOX.PA)?
How does the current ROE for NOXXON Pharma N.V. (ALNOX.PA) compare to its historical average?